180 Life Sciences Corp
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
FRMM$2.82-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| Current Assets: | ||
| Cash | $194,920 | $1,975,799 |
| Prepaid expenses and other current assets | 1,030,461 | 1,664,107 |
| Total Current Assets | 1,225,381 | 3,639,906 |
| Intangible assets, net | 9,244,475 | 1,619,570 |
| Total Assets | $10,469,856 | $5,259,476 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $2,090,827 | $1,892,611 |
| Accounts payable - related parties | 580,830 | 266,009 |
| Accrued expenses | 466,335 | 1,869,814 |
| Loans payable - current portion | 473,143 | 1,034,124 |
| Class B Convertible Preferred stock liability, $0.0001 par value, 1,000,000 shares authorized, issued and outstanding | 2,772,695 | - |
| Derivative liabilities | - | 58 |
| Total Current Liabilities | 6,383,830 | 5,062,616 |
| Loans payable - noncurrent portion | 10,574 | 19,936 |
| Deferred tax liability | 341,678 | 304,657 |
| Total Liabilities | 6,736,082 | 5,387,209 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ Equity (Deficit): | ||
| Preferred stock, $0.0001 par value; 5,000,000 shares authorized; (see designations and shares authorized for Series A, Class C and Class K preferred stock) | ||
| Class C Preferred Stock; 1 share authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | - | - |
| Class K Preferred Stock; 1 share authorized, 1 and 0 shares issued and outstanding, at September 30, 2024 and December 31, 2023, respectively | - | - |
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 1,026,930 and 534,719 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 103 | 54 |
| Additional paid-in capital | 135,955,083 | 130,117,209 |
| Accumulated other comprehensive income | (2,983,072) | (2,901,339) |
| Accumulated deficit | (129,238,340) | (127,343,657) |
| Total Stockholders’ Equity (Deficit) | 3,733,774 | (127,733) |
| Total Liabilities and Stockholders’ Equity (Deficit) | $10,469,856 | $5,259,476 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.